Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monika Engelhardt

Showing results (111-120 of 227) with videos related to

Pageof 23
Sort By:
Annals of Hematology|November 17, 2022
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumabTim Strüßmann, Johannes Jung, Jürgen Heinz, et al.
Cancers|September 10, 2021
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related FactorsLaura Gengenbach, Giulia Graziani, Heike Reinhardt, et al.
Leukemia & Lymphoma|November 30, 2019
Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis<sup>.</sup>Giulia Graziani, Georg W Herget, Gabriele Ihorst, et al.
Annals of Hematology|September 14, 2023
Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenariansMartin Philipp Dieterle, Gila Mostufi-Zadeh-Haghighi, Jan Wilhelm Kus, et al.
Haematologica|April 4, 2020
Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced ageMonika Engelhardt, Gabriele Ihorst, Jesus Duque-Afonso, et al.
Oncotarget|April 19, 2017
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivoDominik Schnerch, Julia Schüler, Marie Follo, et al.
British Journal of Haematology|June 24, 2017
Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantationTim Strüßmann, Kristina Fritsch, Axel Baumgarten, et al.
American Journal of Cancer Research|August 6, 2021
Targeting mitotic exit in solid tumorsChristine Greil, Julia Felthaus, Marie Follo, et al.
British Journal of Haematology|February 7, 2013
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerizationJosefina Udi, Julia Schüler, Dagmar Wider, et al.
Clinical and Experimental Nephrology|August 22, 2018
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort studyAndrea Schmidts, Julian Grünewald, Martina Kleber, et al.
Pageof 23

Showing results (111-120 of 227) with videos related to

Sort By:
Pageof 23
Annals of Hematology|November 17, 2022
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumabTim Strüßmann, Johannes Jung, Jürgen Heinz, et al.
Cancers|September 10, 2021
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related FactorsLaura Gengenbach, Giulia Graziani, Heike Reinhardt, et al.
Leukemia & Lymphoma|November 30, 2019
Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis<sup>.</sup>Giulia Graziani, Georg W Herget, Gabriele Ihorst, et al.
Annals of Hematology|September 14, 2023
Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenariansMartin Philipp Dieterle, Gila Mostufi-Zadeh-Haghighi, Jan Wilhelm Kus, et al.
Haematologica|April 4, 2020
Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced ageMonika Engelhardt, Gabriele Ihorst, Jesus Duque-Afonso, et al.
Oncotarget|April 19, 2017
Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivoDominik Schnerch, Julia Schüler, Marie Follo, et al.
British Journal of Haematology|June 24, 2017
Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantationTim Strüßmann, Kristina Fritsch, Axel Baumgarten, et al.
American Journal of Cancer Research|August 6, 2021
Targeting mitotic exit in solid tumorsChristine Greil, Julia Felthaus, Marie Follo, et al.
British Journal of Haematology|February 7, 2013
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerizationJosefina Udi, Julia Schüler, Dagmar Wider, et al.
Clinical and Experimental Nephrology|August 22, 2018
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort studyAndrea Schmidts, Julian Grünewald, Martina Kleber, et al.
Pageof 23